SERUM ZINE AND COPPER LEVELS OF EPILEPTIC PATIENTS BEFORE AND AFTER DRUG THERAPY ✓ In 42 epileptic patients the serum levels of copper (Cu) and zinc (zn) were determined before drug therapy had begun by atomic absorption spectrophotometry. In 16 of these patients the serum levels of Zn and Cu were also determined at least 3 months after therapy. The results were compared with each other and a control comprising 20 healthy individuals. The mean serum Zn levels of the patients prior to drug therapy, undergoing therapy and the control group were 79.42+17.7 , 83.6+18.3 and 86.95+ 18.61 Hg/100 ml respectively. The mean serum copper levels of the patients prior to therapy, undergoing therapy and the control group were 117+ 21.9, 123.1+18.4 and 119.4, respectively. There were no statistically significant differences bet¬ween the groups (p> 0.05). Serum Zn levels decreased in patients using diphenylhydantoin (DDH) and increased in patients using carbamazepin (CBZ). But, neither of these results were statistically significant. However, serum Cu levels increased significantly in patients using CBZ (p0,05). Difenilhidantoin (DPH) kullanan hastalarda serum Zn düzeyinde azalma, Cu düzeyinde ise artış saptandı. Fakat sonuçlar istatistiksel olarak anlamsızdı. Yalnız karbamazepin (CBZ) kullanan hastalarda serum Cu düzeyinde anlamlı artış görüldü (p